Journal List > Dement Neurocogn Disord > v.13(2) > 1120725

Dement Neurocogn Disord. 2014 Jun;13(2):27-36. Korean.
Published online Jun 30, 2014.
© 2014 Korean Dementia Association
Depression in Alzheimer's Disease
Yong Tae Kwak, M.D.,* YoungSoon Yang, M.D., and Min-Seong Koo, M.D.
*Department of Neurology, Hyoja Geriatric Hospital, Yongin, Korea.
Department of Neurology, Seoul Veterans Hospital, Seoul, Korea.
Department of Psychiatry, College of Medicine, Kwandong University, Gangnung, Korea.

Address for correspondence: Yong Tae Kwak, M.D. Department of Neurology, Hyoja Geriatric Hospital, 1-30 Jungbu-daero 874 beon-gil, Giheung-gu, Yongin 446-512, Korea. Tel: +82-31-288-0602, Fax: +82-31-288-0539, Email:
Received May 10, 2014; Revised May 28, 2014; Accepted May 28, 2014.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Depression is one of the most common psychiatric complications of Alzheimer disease (AD), affecting from 30% to 50% of prevalence, with most estimates in the 20-30% range. Because of having a presentation in the context of AD that differs from typical early-onset depression, it is not easy one to detect and quantify reliably, and can be difficulty to differentiate depression from the other neuropsychiatric symptoms of AD. Due to the lack of large randomized trials, optimal treatment and the true degree of efficacy remains undetermined. However, these treatments can reduce adverse impact of depression on patients and caregivers. This article provides a practical discussion of the diagnosis, evaluation, differential diagnosis and treatment of depression in AD for the clinician.

Keywords: Depression; Alzheimer's disease; Early-onset depression


Table 1
Provisional diagnostic criteria for depression of AD
Click for larger image


We have no conflicts of interests.

1. Devier DJ, Villemarette-Pittman N, Brown P, Pelton G, Stern Y, Sano M, et al. Predictive utility of type and duration of symptoms at initial presentation in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2010;30:238–244.
2. Wilson RS, Mendes De Leon CF, Bennet DA, Bienias JL, Evans DA. Depressive symptoms and cognitive decline in a community population of older persons. J Neurol Neurosurg Psychiatry 2004;75:126–129.
3. Devanand DP, Sano M, Tang Mx, Taylor S, Gurland BJ, Wilder D, et al. Depressed mood and the incidence of Alzheimer's disease in elderly living in the community. Arch Gen Psychiatry 1996;53:175–182.
4. Wilson RS, Barnes LL, Mendes De Leon CF, Aggarwal NT, Schneider JS, Bach J, et al. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology 2002;59:364–370.
5. Fuhrer R, Dufouil C, Dartigues JF. PAQUID Study. Exploring sex differences in the relationship between depressive symptoms and dementia incidence: prospective results from the PAQUID Study. J Am Geriatr Soc 2003;51:1055–1063.
6. Gonzáles-Salvador T, Lyketsos CG, Baker AS, Roques C, Hovanek L, Steele CD, et al. Quality of life of patients with dementia in long-term care. Int J Geriatr Psychiatry 2000;15:181–189.
7. Harwood DG, Barker WW, Ownby RL, Duara R. Association between premorbid history of depression and current depression in Alzheimer's disease. J Geriatr Psychiatry Neurol 1999;12:72–75.
8. Lyketsos CG, Steele C, Galik E, Rosenblatt A, Steinberg M, Warren A, et al. Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry 1999;156:66–71.
9. Gonzáles-Salvador MT, Aragano C, Lyketsos CG, Barba AC. The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry 1999;14:701–710.
10. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147:1049–1051.
11. Lyketsos CG, Baker L, Warren A, Steele C, Brandt J, Steinberg M, et al. Major and minor depression in Alzheimer's disease: prevalence and impact. J Neuropsychiatry Clin Neurosci 1997;9:556–561.
12. Weiner MF, Doody RS, Sairam R, Foster B, Liao TY. Prevalence and incidence of major depressive disorder in Alzheimer's disease: findings from two databases. Dement Geriatr Cogn Disord 2002;13:8–12.
13. Forsell Y, Winblad B. Major depression in a population of demented and nondemented old people: prevalence and correlates. J Am Geriatr Soc 1998;46:27–30.
14. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288:1475–1483.
15. Payne JL, Sheppard JM, Steinberg M, Warren A, Baker A, Steele C, et al. Incidence, prevalence, and outcomes of depression in residents of a long term care facility with dementia. Int J Geriatr Psychiatry 2002;17:247–253.
16. Teng E, Lu PH, Cummings JL. Neuropsychiatric symptoms are associated with progression from mild cognitive impairment toAlzheimer's disease. Dement Geriatr Cogn Disord 2007;24:253–259.
17. Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996;153:1438–1443.
18. Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry 2002;10:129–141.
19. Holtzer R, Scarmeas N, Wegesin DJ, Albert M, Brandt J, Dubois B. Depressive symptoms in Alzheimer's disease: natural course and temporal relation to function and cognitive status. J Am Geriatr Soc 2005;53:2083–2089.
20. Wilson RS, Hoganson GM, Rajan KB, Barnes LL, Mendes de Leon CF, Evans DA. Temporal course of depressive symptoms during the development of Alzheimer disease. Neurology 2010;75:21–26.
21. Kwak YT, Yang Y, Pyo SJ, Koo MS. Clinical characteristics according to depression screening tools in patients with Alzheimer's disease: view from self, caregiver-reported and drug-intervention pattern. Geriatr Gerontol Int 2013;13:701–707.
22. Kwak YT, Yang Y, Kwak SG. Clinical characteristics of behavioral and psychological symptoms in patients with drug-naive Alzheimer's disease. Dement Neurocogn Disord 2012;11:87–94.
23. Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology 2010;75:35–41.
24. Andersen K, Lolk A, Kragh-Sørensen P, Petersen NE, Green A. Depression and the risk of Alzheimer disease. Epidemiology 2005;16:233–238.
25. Gatz JL, Tyas SL, St John P, Montgomery P. Do depressive symptoms predict Alzheimer's disease and dementia? J Gerontol A Biol Sci Med Sci 2005;60:744–747.
26. Chen R, Hu Z, Wei L, Qin X, McCracken C, Copeland JR. Severity of depression and risk for subsequent dementia: cohort studies in China and the UK. Br J Psychiatry 2008;193:373–377.
27. Byers AL, Covinsky KE, Barnes DE, Yaffe K. Dysthymia and depression increase risk of dementia and mortality among older veterans. Am J Geriatr Psychiatry 2012;20:664–672.
28. Irie F, Masaki KH, Petrovitch H, Abbott RD, Ross GW, Taaffe DR, et al. Apolipoprotein E epsilon4 allele genotype and the effect of depressive symptoms on the risk of dementia in men: the Honolulu-Asia Aging Study. Arch Gen Psychiatry 2008;65:906–912.
29. Geerlings MI, Schmand B, Braam AW, Jonker C, Bouter LM, van Tilburg W. Depressive symptoms and risk of Alzheimer's disease in more highly educated older people. J Am Geriatr Soc 2000;48:1092–1097.
30. Becker JT, Chang YF, Lopez OL, Dew MA, Sweet RA, Barnes D. Depressed mood is not a risk factor for incident dementia in a community-based cohort. Am J Geriatr Psychiatry 2009;17:653–663.
31. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002;156:445–453.
32. Vinkers DJ, Gussekloo J, Stek ML, Westendorp RG, van der Mast RC. Temporal relation between depression and cognitive impairment in old age: prospective population based study. BMJ 2004;329:881.
33. Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberguer-Gateau P, et al. Prodromal Alzheimer's disease: sucessive emergence of the clinical symptoms. Ann Neurol 2008;64:492–498.
34. Dal Forno G, Palermo MT, Donohue JE, Karagiozis H, Zonderman AB, Kawas CH. Depressive symptoms, sex, and risk for Alzheimer's disease. Ann Neurol 2005;57:381–387.
35. Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 2010;75:27–34.
36. Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA. Mid-life versus late-life depressive symptoms and risk of dementia: differential effects for Alzheimer's disease and vascular dementia. Arch Gen Psychiatry 2012;69:493–498.
37. Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, et al. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol 2003;60:753–759.
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition, Text Revision. Washington, DC: American Psychiatric Press; 2000.
39. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
40. Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, et al. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am J Psychiatry 2003;160:857–866.
41. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry 1988;23:271–284.
42. Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, et al. Provisional diagnostic criteria for depression of Alzheimer's disease. Am J Geriatr Psychiatry 2002;10:125–128.
43. Teng E, Ringman JM, Ross LK, Mulnard RA, Dick MB, Bartzokis G, et al. Diagnosing depression in Alzheimer's disease with the national institute of mental health provisional criteria. Am J Geriatr Psychiatry 2008;16:469–477.
44. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.
45. Debruyne H, Van Buggenhout M, Le Bastard N, Aries M, Audenaert K, De Deyn PP, et al. Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment? Int J Geriatr Psychiatry 2009;24:556–562.
46. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987;48:9–15.
47. Tariot PN, Mack JL, Patterson MB. The behavior rating scale for dementia of the Consortium to establish a Registry for Alzheimer's disease. Am J Psychiatry 1995;152:1349–1357.
48. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–2314.
49. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982-1983;17:37–49.
50. Heun R, Kockler M, Ptok U. Depression in Alzheimer's disease: is there a temporal relationship between the onset of depression and the onset of dementia? Eur Psychiatry 2002;17:254–258.
51. Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998;6:S64–S78.
52. Whitford GM. Alzheimer's disease and serotonin: a review. Neuropsychobiology 1986;15:133–142.
53. Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, et al. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 1998;18:407–430.
54. Gareri P, De Fazio P, Sarro G. Neuropharmacology of depression in aging and age-related diseases. Ageing Res Rev 2002;1:113–134.
55. Forstl H, Burns A, Luthert P. Clinical and neuropathological correlates of depression in Alzheimer's disease. Psychol Med 1992;22:877–884.
56. Zubenko GS. Biological correlates of clinical heterogeneity in primary dementia. Neuropsychopharmacology 1992;6:77–93.
57. Zweig RM, Ross CA, Hedreen JC, Steele C, Cardillo JE, Whitehouse PJ, et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 1988;24:233–242.
58. Palmer AM, Stratmann GC, Procter AW, Bowen DM. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann Neurol 1988;23:616–620.
59. Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of major depression in primary dementia. Arch Neurol 1990;47:209–214.
60. Blin J, Baron JC, Dubois B, Crouzel C, Fiorelli M, Attar-Lévy D, et al. Loss of brain 5HT2 receptors in Alzheimer's disease: In vivo assessment with positron emission tomography and 18F setoperone. Brain 1993;116:497–510.
61. Rapp MA, SchneiderBeeri M, Purohit DP, Perl DP, Haroutunian V, Sano M. Increased neurofibrillary tangles in patients with Alzheimer's disease with comorbid depression. Am J Geriatr Psychiatry 2008;16:168–174.
62. Wilson RS, Schneider JA, Bienias JL, Arnold SE, Evans DA, Bennet DA. Depressive symptoms, clinical AD, and cortical plaques and tangles in older persons. Neurology 2003;61:1102–1107.
63. Teri L, Logsdon RG, Uomoto J, McCurry SM. Behavioral treatment of depression in dementia patients: a controlled clinical trial. J Gerontol B Psychol Sci Soc Sci 1997;52:P159–P166.
64. Teri L, Gibbons LE, McCurry SM, Logsdon RG, Buchner DM, Barlow WE, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 2003;290:2015–2022.
65. DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005;62:409–416.
66. Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD, Salomon RM, O'Reardon JP, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005;62:417–422.
67. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, Baker AS, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003;60:737–746.
68. Petracca G, Tesón A, Chemerinski E, Leiguarda R, Starkstein SE. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1996;8:270–275.
69. Fuchs A, Hehnke U, Erhart C, Schell C, Pramshohler B, Danninger B, et al. Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry 1993;26:37–41.
70. Roth M, Mountjoy CQ, Amrein R. Meclobemide in elderly patients with cognitive decline and depression. An international double-blind, placebo-controlled trial. Br J Psychiatry 1996;168:149–157.
71. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990;157:894–901.
72. Rosenberg PB, Drye LT, Martin BK, Martin BK, Frangakis C, Mintzer JE, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 2010;18:136–145.
73. Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011;378:403–411.
74. de Vasconcelos Cunha UG, Lopes Rocha F, Avila de Melo R, Alves Valle E, de Souza Neto JJ, Mendes Brega R, et al. A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. Dement Geriatr Cogn Disord 2007;24:36–41.
75. Reifler BV, Teri L, Raskind M, Veith R, Barnes R, White E, et al. Double-blind trial of Imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 1989;146:45–49.
76. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 2001;13:233–240.
77. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc 2011;59:577–585.
78. Lyketsos CG, Sheppard JM, Steele CD, Kopunek S, Steinberg M, Baker AS, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Am J Psychiatry 2000;157:1686–1689.
79. Petracca GM, Chemerinski E, Starkstein SE. A doubleblind placebo-controlled study of Fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 2001;13:233–240.
80. Munro CA, Brandt J, Sheppard JM, Steele CD, Samus QM, Steinberg M, et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the depression in Alzheimer's disease study (DIADS). Am J Geriatr Psychiatry 2004;12:491–498.
81. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Weiying Y. Reduction of behavioural disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 2004;161:532–538.
82. Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P. Donepezil MSAD study investigators group. Functional, cognitive, and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin 2002;18:347–354.
83. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999;56:1388–1393.
84. Pinheiro D. Anticonvulsantmood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD). Encephale 2008;34:409–415.
85. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: Phase 1 outcomes from the CATIEAD effectiveness trial. Am J Psychiatry 2008;165:844–854.
86. Rao V, Lyketsos CG. The benefits and risks of ECT for patients with degenerative dementia who also suffer from depression. Int J Geriatr Psychiatry 2000;15:729–735.
87. Rabins PV, Lyketsos CG, Steele CD. In: Practical dementia care. New York: Oxford University Press; 1999.
88. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107–115.
89. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998;155:54–61.
90. Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001;9:58–66.